Global Rituximab Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Rituximab Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Rituximab is a type of antibody therapy that can be used alone or with chemotherapy.
Rituximab report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rituximab market is projected to reach US$ 6006.3 million in 2029, increasing from US$ 10350 million in 2022, with the CAGR of -5.2% during the period of 2024 to 2029. Demand from Intravenous Use and Subcutaneous Use are the major drivers for the industry.
Revlimid, an oral medication used in the treatment of multiple myeloma and other blood cancers, is experiencing increasing demand. Factors driving market growth include the rising incidence of blood cancers, advancements in treatment options, and the expanding geriatric population. Key players in the market are focusing on expanding the indications of Revlimid and conducting clinical trials for new indications. Additionally, strategic collaborations and mergers are contributing to market expansion. However, challenges such as patent expirations and the availability of generic alternatives may impact market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rituximab market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Roche
Pfizer
Biogen
Teva
Segment by Type
500mg
100mg
Intravenous Use
Subcutaneous Use
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rituximab market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rituximab, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rituximab industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rituximab in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rituximab introduction, etc. Rituximab Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Rituximab market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Rituximab report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Rituximab market is projected to reach US$ 6006.3 million in 2029, increasing from US$ 10350 million in 2022, with the CAGR of -5.2% during the period of 2024 to 2029. Demand from Intravenous Use and Subcutaneous Use are the major drivers for the industry.
Revlimid, an oral medication used in the treatment of multiple myeloma and other blood cancers, is experiencing increasing demand. Factors driving market growth include the rising incidence of blood cancers, advancements in treatment options, and the expanding geriatric population. Key players in the market are focusing on expanding the indications of Revlimid and conducting clinical trials for new indications. Additionally, strategic collaborations and mergers are contributing to market expansion. However, challenges such as patent expirations and the availability of generic alternatives may impact market growth.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Rituximab market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Roche
Pfizer
Biogen
Teva
Segment by Type
500mg
100mg
Segment by Application
Intravenous Use
Subcutaneous Use
Segment by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Rituximab market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Rituximab, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Rituximab industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Rituximab in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Rituximab introduction, etc. Rituximab Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Rituximab market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices